Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
Arch Womens Ment Health. 2002 Nov;5(3):99-104.

A clinical trial of adjunctive oestrogen treatment in women with schizophrenia.

Author information

  • 1Dandenong Psychiatry Research Centre, Monash University Department of Psychological Medicine, Melbourne, Australia. jayashri.kulkarni@med.monash.edu.au

Abstract

A double-blind, 28-day, placebo-controlled study was conducted with three groups of women of child-bearing age (N = 12 in each group) who received standardised antipsychotic medication plus a) 50 microg transdermal estradiol or b) 100 microg transdermal estradiol or c) transdermal placebo. Preliminary analyses show that women receiving 100 microg of estradiol made greater improvements in the symptoms of schizophrenia than either the 50 microg estradiol or placebo groups. The addition of 100 microg adjunctive transdermal oestrogen significantly enhanced treatment responsivity of acute, severe psychotic symptoms in women with schizophrenia. The positive impact of oestrogen treatment on psychotic symptoms via a multiplicity of possible actions (see accompanying articles in this issue) may prove clinically useful in the overall treatment of women with schizophrenia.

PMID:
12510212
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Springer
    Loading ...
    Write to the Help Desk